Navigation Links
For ST-Elevation Myocardial Infarction (STEMI), Interviewed Experts Indicate That The Medicines Company's Angiomax/Angiox Has Efficacy Advantages Over Sales-Leading ReoPro
Date:4/23/2009

Angiomax/Angiox Will Retain Decision Resources' Gold-Standard Status in 2017 for the Treatment of STEMI with Percutaneous Coronary Intervention, According to a New Report from Decision Resources

WALTHAM, Mass., April 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists identify a therapy's effect on mortality as the attribute that most influences their prescribing decisions in the treatment of ST-elevation myocardial infarction (STEMI). Clinical data and the opinions of interviewed thought leaders indicate that The Medicines Company's Angiomax/Angiox has advantages in this attribute over Eli Lilly's ReoPro, the sales-leading agent in percutaneous coronary intervention (PCI) treatment of STEMI.

The new report entitled STEMI: Significant Opportunity Awaits Drugs That Can Reduce Mortality Rates also finds that an antiplatelet agent administered with stenting that is associated with lower rates of mortality and thrombocytopenia than ReoPro and less severe drug interactions would earn a substantial patient share in STEMI. According to surveyed U.S. and European cardiologists, this patient share would be 50 percent in the United States and 40 percent in Europe.

In 2008, Decision Resources' proprietary clinical gold standard for STEMI treated with PCI was Angiomax/Angiox. Based on available data and expert opinion, Angiomax/Angiox will retain gold-standard status for STEMI in 2017. While some therapies in development for the treatment of STEMI with PCI hold promise, most have efficacy, safety and tolerability, and/or delivery features that interviewed physicians indicate are inferior when compared with Angiomax/Angiox.

"Interviewed physicians regard Angiomax/Angiox as being highly efficacious because it is associated with significantly lower mortality rates than the standard PC
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. An ESC statement on gender differences in medical care and survival after myocardial infarction
2. New System Devised To Guide Doctors Treating Patients With Symptomatic Myocardial Bridging
3. New system devised to guide doctors treating patients with symptomatic myocardial bridging
4. Myocardial infarction: Mortality for women not higher than for men
5. Increased risk of myocardial infarction and diabetes in East Germany
6. Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientific Sessions
7. Heart regenerates after infarction -- first trials with mice
8. ST elevation infarction
9. Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer
10. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
11. My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
(Date:4/24/2014)... first flu pandemic in the 21st century. The virus ... 50 people in the country. Since 2011 the pH1N1 ... , Infections with influenza pH1N1 virus vary from ... recommended Tamiflu for treatment of patients with severe or ... it targets viral proteins which mutate quickly and the ...
(Date:4/23/2014)... clinical trials for a new experimental drug to ... Patients treated with CPX-351, a combination of the ... responses than patients treated with the standard drug ... is an aggressive blood cancer with very low ... explained Jeffrey Lancet, M.D., senior member of the ...
(Date:4/23/2014)... high-energy particles, simulating conditions astronauts would face on a ... slower reaction times, even when the radiation exposure is ... which affected a large subset, but far from ... to protein changes in the brain, the scientists say. ... suggest it may be possible to develop a biological ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... Satori World Medical, ... certain providers of Sistemas Medicos Nacionales, S.A. de C.V. (SIMNSA) to its network in Mexico. ... San Diego, CA ... in the emerging medical tourism industry, announced the addition of certain providers of Sistemas Medicos ...
... 14 Continuing its efforts to educate, inform, and ... not-for-profit patient-focused organization, is hosting its 25-minute live call-in ... on Monday, October 19, 2009 at 6:00 PM on ... a frank discussion regarding Retail Health Clinics with Erin ...
... HARBIN, China, Oct. 14 /PRNewswire-Asia-FirstCall/-- SOKO Fitness ... of fitness centers,and beauty salons and spas in Northeast China, ... Officer Yu Xia, and,Corporate Secretary Jiang Judy will host a ... 9 am EDT on Oct. 16. , , ...
... of altruism , WEDNESDAY, Oct. 14 (HealthDay News) ... they,re not likely to offer help voluntarily, say researchers ... Japanese research team studied six pairs of chimpanzees (three ... designed to find out whether a chimpanzee would give ...
... ... feature the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at the 23rd ... , ... Arbor, Mich. (PRWEB) -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, ...
... BNVI ) announced today the appointment of Dr. Debu ... Program at the University Southern California, to the company,s Medical ... researcher in the area of breast cancer. , "We ... in the area of breast cancer join our Medical Advisory ...
Cached Medicine News:Health News:SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Retail Health Clinics - The Real Story 2Health News:SOKO Fitness & Spa Group, Inc. to Hold FY 2010 Q1 Earnings Call on Oct. 16 2Health News:SOKO Fitness & Spa Group, Inc. to Hold FY 2010 Q1 Earnings Call on Oct. 16 3Health News:If You Want Help From a Chimp, You'll Have to Ask 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 3Health News:Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board 2Health News:Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board 3
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , , , ... Claims and Clearinghouse Service in the 2009 Top 20 ... RealMed is a dynamic revenue cycle management solution providing advanced, ... payers. KLAS is an independent research firm specializing in ...
... ... today announced a series of flexible financing solutions ... and meet deadlines defined within the HITECH provision of the ... interest terms for qualified customers, the solutions enable organizations to ...
Cached Medicine Technology:RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4
The new, single-use 26 mL applicator is latex-free, hands-off and sterile to help prevent cross-contamination. The applicator is designed for a smooth delivery of the solution for larger surgical pro...
... Anti-HCV Low Titer Performance Panel consists of ... to strong positive for antibodies to the ... for use by manufacturers and diagnostic laboratories ... from all major test systems are included ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
... a biological material derived from ... for excellent suppleness and strength. ... ensure high levels of quality ... enhances the biocompatibility, performance and ...
Medicine Products: